-
News | 2022.12.27
Bicentenary of Louis Pasteur's birth: looking back on a year of commemorations
Two hundred years ago, on December 27, 1822, Louis Pasteur was born in the town of Dole, in the Jura region of France. The year 2022 was an opportunity to celebrate Louis Pasteur's scientific and cultural legacy and to give people a chance to discover – or rediscover – his life and work.
-
News | 2025.03.20
An international scientific alliance to strengthen the fight against infectious diseases
The Institut Pasteur and UCSF-QBI celebrated an ongoing successful scientific collaboration today, which was initiated in March 2019, and expanded significantly during the pandemic. This alliance, formalized in October 2022, aimed at bolstering the fight against infectious diseases, has already spawned more than 20 research projects, a dozen publications in high-level journals, and numerous...
-
Article | 2023.02.23
One Health-Emerging Infectious Diseases Graduate School (1H-EID)
The new Graduate School "One Health in Emerging Infectious Diseases" (1H-EID) is entirely dedicated to EIDs with a multidisciplinary approach. This Graduate School offers a high-level educational program based on research, to train future researchers, health professionals and decision-makers.The aim of 1H-EID will be to form a community of frontline actors, researchers and decision-makers,all...
-
News | 2019.02.21
A research ethics committee at the Institut Pasteur since 2009
The Institut Pasteur Institutional Review Board (IRB) protects the rights and safety of participants in research carried out by the Institut Pasteur abroad. Since it was set up in 2009, it has monitored nearly 50 international research projects involving human subjects. The Board is currently chaired by Dr. Gilles Raguin, a physician specializing in infectious diseases. We asked him to tell us...
-
News | 2020.05.20
Blood test: a potential new tool for controlling infections
A new technique could provide vital information about a community’s immunity to infectious diseases including malaria and Covid-19.The diagnostic test analyses a blood sample to reveal immune markers that indicate whether – and when – a person was exposed to an infection. It was developed to track malaria infections in communities, to assist in the elimination of deadly ‘relapsing’ malaria, but...
-
Document de presse | 2020.04.30
Revealing how SARS-CoV-2 hijacks human cells; points to drugs with potential to fight COVID-19 and a drug that aids its infectious growth
An international effort including researchers from University of California San Francisco (UCSF), Gladstone Institutes, Icahn School of Medicine at Mount Sinai and Institut Pasteur (Paris) unveils promising compounds for clinical testing against COVID-19. The study, led by UCSF Quantitative Biosciences Institute Director, Nevan Krogan, PhD, reveals that some drugs may fight COVID-19...
-
News | 2020.05.14
LuLISA project, bioluminescence as a tool for human diagnostics, from allergy to Covid19
The LuLISA (Luciferase-Linked ImmunoSorbent Assay) research project aims developing high throughput serological tests for epidemiological studies at local, regional or nation scales. In a recent scientific publication, concerning the detection and dosing of IgE specific to several allergens in patients’ blood samples, the use of LuLISA proves to be a vastly improved detection method in...
-
Fiche maladie | 2022.06.03
Autism
Autism is a neurodevelopmental disorder (NDD). It appears in early childhood (before the age of 36 months) and affects children's developmental areas in different ways and to different degrees. In most cases, its effects impact on autistic individuals' level of independence and social interaction and participation. It is therefore important to diagnose the condition and take action as early as...